Bioequivalence Article originally published in Encyclopedia of Biostatistics, 2nd Edition (2005, John Wiley & Sons, Ltd).

Bioequivalence is defined as the comparable bioavailability of alternative drug formulations. Kinetic measures of bioavailability are reviewed, leading to a discussion of the statistical assessment of bioequivalence. Parametric and nonparametric methods of testing are described. Current research areas, including the estimation of individual bioequivalence and alternative measures for the evaluation of bioequivalence, are reviewed.

References

1 Chow, S.C. & Liu, J.P. (1992). Design and Analysis of Bioavailability and Bioequivalence Studies, Marcel Dekker, New York.
Google Scholar
2 Sauter, R., Steinijans, V.W., Diletti, E., Böhm, A. & Schulz, H.-U. (1992). Presentation of results from bioequivalence studies, International Journal of Clinical Pharmacology, Therapeutics and Toxicology 30, 233–256.
CAS PubMed Web of Science® Google Scholar
3 Yee, K.F. (1986). The calculation of probabilities in rejecting bioequivalence, Biometrics 42, 961–965.
10.2307/2530711
CAS PubMed Web of Science® Google Scholar
4 Schuirmann, D.J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability, Journal of Pharmacokinetics and Biopharmaceutics 15, 657–680.
10.1007/BF01068419
CAS PubMed Web of Science® Google Scholar
5 Westlake, W.J. (1981). Bioequivalence testing—a need to rethink, Biometrics 37, 589–594.
10.2307/2530573
PubMed Web of Science® Google Scholar
6 Steinijans, V.W. & Hauschke, D. (1990). Update on the statistical analysis of bioequivalence studies, International Journal of Clinical Pharmacology, Therapeutics and Toxicology 28, 105–110.
CAS PubMed Web of Science® Google Scholar
7 Westlake, W.J. (1988). Bioavailability and bioequivalence of pharmaceutical formulations, in Biopharmaceutical Statistics for Drug Development, K.E. Peace, ed, Marcel Dekker, New York, pp. 329–352.
Google Scholar
8 Hauschke, D., Steinijans, V.W. & Diletti, E. (1990). A distribution-free procedure for the statistical analysis of bioequivalence studies, International Journal of Clinical Pharmacology, Therapeutics and Toxicology 28, 72–78.
CAS PubMed Web of Science® Google Scholar
9 Anderson, S. & Hauck, W.W. (1990). Considerations of individual bioequivalence, Journal of Pharmacokinetics and Biopharmaceutics 18, 259–273.
10.1007/BF01062202
CAS PubMed Web of Science® Google Scholar
10 Anderson, S. (1993). Individual bioequivalence: a problem of switchability (with discussion), Biopharmaceutics Report 22, 1–11.
Web of Science® Google Scholar
11 Schall, R. (1995). Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar, Biometrics 51, 615–626.
10.2307/2532949
CAS PubMed Web of Science® Google Scholar
12 Schall, R. & Luus, H.E. (1993). On population and individual bioequivalence, Statistics in Medicine 12, 1109–1124.
10.1002/sim.4780121202
CAS PubMed Web of Science® Google Scholar
13 Sheiner, L.B. (1992). Bioequivalence revisited, Statistics in Medicine 11, 1777–1788.
10.1002/sim.4780111311
CAS PubMed Web of Science® Google Scholar
14 Holder, D.J. & Hsuan, F. (1993). Moment-based criteria for determining bioequivalence, Biometrika 80, 835–846.
10.1093/biomet/80.4.835
Web of Science® Google Scholar
15 Schall, R. (1995). Unified view of individual, population and average bioequivalence, in BioInternational 2: Bioavailability, Bioequivalence and Pharmacokinetic Studies, H.H. Blume & K.K. Midha, eds, Medpharm, Stuttgart, pp. 91–106.
Web of Science® Google Scholar
16 Cartwright, A.C., Gundert-Remy, U., Rauws, G., McGilveray, I., Salmonson, T. & Walters, S. (1991). International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing requirements and standards, Drug Information Journal 25, 471–482.
10.1177/009286159102500402
Google Scholar
17 Zha, J. & Endrenyi, L. (1997). Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence, Journal of Biopharmaceutical Statistics 7, 191–204.
10.1080/10543409708835179
CAS PubMed Google Scholar
18 Chen, M.L. (1992). An alternative approach for assessment of rate of absorption in bioequivalence studies, Pharmaceutical Research 9, 1380–1385.
10.1023/A:1015842425553
CAS PubMed Web of Science® Google Scholar
19 Endrenyi, L. & Al-Shaikh, P. (1995). Sensitive and specific determination of the equivalence of absorption rates, Pharmaceutical Research 12, 1856–1864.
10.1023/A:1016267200905
CAS PubMed Web of Science® Google Scholar
20 Endrenyi, L., Fritsch, S. & Yan, W. (1991). C_max/AUC is a clearer measure than C_max for absorption rates in investigations of bioequivalence, International Journal of Clinical Pharmacology, Therapeutics and Toxicology 29, 394–399.
PubMed Web of Science® Google Scholar
21 Steinijans, V.W., Sauter, R., Jonkman, J.H.G., Schulz, H.U., Stricker, H. & Blume, H. (1989). Bioequivalence studies: single vs multiple doses, International Journal of Clinical Pharmacology, Therapeutics and Toxicology 27, 261–266.
CAS PubMed Web of Science® Google Scholar

Encyclopedia of Quantitative Risk Analysis and Assessment

Browse other articles of this reference work:

Bioequivalence

Article originally published in Encyclopedia of Biostatistics, 2nd Edition (2005, John Wiley & Sons, Ltd).

Abstract

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Abstract

References

References

Related

Information

Bioequivalence

Article originally published in Encyclopedia of Biostatistics, 2nd Edition (2005, John Wiley & Sons, Ltd).